Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 versus Prevnar 13 in healthy infants
2010-019775-29Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2010
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of pneumococcal 15-valent conjugate vaccine and Prevnar 13 in pneumococcal disease, invasive pneumococcal disease (IPD), Pneumococcal pneumonia (PP) and 2 more (3 arms), sponsored by Merck & Co. Primary endpoints: Primary immunogenicity endpoint for 7 shared serotypes and Primary objective for additional 6 shared serotypes with Prevnar 13. Started Jul 2010; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccinePrevnar 13
03
Conditions
pneumococcal diseaseinvasive pneumococcal disease (IPD)Pneumococcal pneumonia (PP)otitis mediapneumococcal septicemia
Beyond the preview
Go deeper on 2010-019775-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019775-29.